Azaya Therapeutics Inc., of San Antonio, Texas, said final results from the Phase I study of its cancer drug, ATI-1123 (liposomal docetaxel), showed 79 percent of heavily pretreated patients received benefit from the compound. The 29 patients enrolled in the study suffered from a variety of solid tumors, including cervical, gastric, melanoma, lung, ovarian, pancreatic, prostate, thyroid and uterine cancers.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter